After Recusal, Schnedar Leaving CDER Compliance Office
This article was originally published in The Pink Sheet Daily
Executive Summary
Cynthia Schnedar decides to leave several weeks after FDA determined that her husband's promotion could create conflicts of interest.
You may also be interested in...
US FDA’s New Compliance Chief Donald Ashley Brings International Law Enforcement Experience
Ashley's many years in the Department of Justice’s Office of International Affairs should be a plus for agency's globalization efforts.
Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US
Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.
Show Me The Money: FDA Recruitment Efforts Challenged By Government Salaries
FDA’s Center for Drugs continues to operate under a staffing shortage at a time when it faces tremendous pressure to implement new authorities. In some cases, that’s left Janet Woodcock scrambling to find senior managers that can lead top CDER initiatives. Direct hiring authority has helped, but it doesn’t fully address FDA’s recruiting challenges. There’s still too much red tape – and not enough money.